↓ Skip to main content

Cochrane Database of Systematic Reviews

Cholinesterase inhibitors for Alzheimer's disease

Overview of attention for article published in Cochrane database of systematic reviews, January 2006
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
4 news outlets
blogs
6 blogs
policy
1 policy source
twitter
35 X users
patent
3 patents
peer_reviews
1 peer review site
wikipedia
35 Wikipedia pages

Citations

dimensions_citation
1529 Dimensions

Readers on

mendeley
1160 Mendeley
citeulike
1 CiteULike
Title
Cholinesterase inhibitors for Alzheimer's disease
Published in
Cochrane database of systematic reviews, January 2006
DOI 10.1002/14651858.cd005593
Pubmed ID
Authors

Jacqueline S Birks

Abstract

Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase. The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease. Cochrane reviews of each ChEI for Alzheimer's disease have been completed (Birks 2005, Birks 2005b and Loy 2005). Despite the evidence from the clinical studies and the intervening clinical experience the debate on whether ChEIs are effective continues.

X Demographics

X Demographics

The data shown below were collected from the profiles of 35 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 1,160 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 8 <1%
United States 6 <1%
Netherlands 2 <1%
Italy 2 <1%
Pakistan 1 <1%
Ireland 1 <1%
Switzerland 1 <1%
Sweden 1 <1%
Brazil 1 <1%
Other 5 <1%
Unknown 1132 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 183 16%
Student > Ph. D. Student 151 13%
Student > Master 143 12%
Researcher 125 11%
Student > Doctoral Student 60 5%
Other 188 16%
Unknown 310 27%
Readers by discipline Count As %
Medicine and Dentistry 244 21%
Agricultural and Biological Sciences 102 9%
Neuroscience 91 8%
Pharmacology, Toxicology and Pharmaceutical Science 65 6%
Biochemistry, Genetics and Molecular Biology 65 6%
Other 237 20%
Unknown 356 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 100. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 February 2024.
All research outputs
#419,377
of 25,383,278 outputs
Outputs from Cochrane database of systematic reviews
#736
of 12,915 outputs
Outputs of similar age
#803
of 168,343 outputs
Outputs of similar age from Cochrane database of systematic reviews
#2
of 60 outputs
Altmetric has tracked 25,383,278 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,915 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 36.1. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 168,343 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 60 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.